Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITESPARK-043 long-term extension study of belzutifan
jRCT2061260008Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of belzutifan in advanced nonhematological malignancy and von Hippel–Lindau disease (VHL), sponsored by Merck & Co. Primary endpoint: Overall survival. Started Jun 2026; status: recruiting.
02
Drugs
belzutifan
03
Conditions
advanced nonhematological malignancyvon Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on jRCT2061260008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260008.